.Attribute Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin caused boosted progression-free and general survival, leading to FDA approval and also a brand new therapy alternative for patients.